Home » “Promising Antineoplastic Effects of GFH009, a Potent and Selective CDK9 Inhibitor, in Hematologic Malignancies: Support from Ongoing Clinical Studies”

“Promising Antineoplastic Effects of GFH009, a Potent and Selective CDK9 Inhibitor, in Hematologic Malignancies: Support from Ongoing Clinical Studies”

by satcit

https://pubmed.ncbi.nlm.nih.gov/38117531

GFH009, a potent and highly selective CDK9 inhibitor, shows promising antineoplastic effects in the treatment of hematologic malignancies by inducing apoptosis and inhibiting tumor growth, as supported by ongoing clinical studies for acute myeloid leukemia and other hematological malignancies.

You may also like

Leave a Comment